^
Association details:
| Biomarker: | PBRM1 mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma.
Published date:
02/14/2020
Excerpt:
This study is investigating the genomic components of tumor antigen presentation in ICB-naïve patients who have RCC and are treated with len/pembro...Loss-of-function mutations in PBRM1 (PBRM1 LOF) trended toward improved PFS...PBRM1 mutation may be associated with improved PFS
Trial ID:
